An Open-Label Study to Assess Safety

An Open-Label study to assess the efficacy and potential for adrenal suppression following
maximal use treatment with TA-102 topical formulations in subjects with Plaque Psoriasis.

Inclusion Criteria:

1. Healthy male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of
plaque psoriasis.

2. Definite clinical diagnosis of stable plaque psoriasis for at least 6 months.

3. Subjects must be in good health and free from any clinically significant disease,
including but not limited to, conditions that may interfere with the evaluation of
plaque psoriasis.

Exclusion Criteria:

1. Female Subjects who are pregnant, nursing or planning to become pregnant during study
participation.

2. History of allergy or sensitivity to retinoid, corticosteroids and/or history of any
drug hypersensitivity or intolerance which, in the opinion of the Investigator, would
compromise the safety of the Subject or the results of the study.